High-dose influenza vaccination reduces hospitalisation risk in adults over 65, but the absolute benefit is modest and varies significantly by individual risk profile. Clinical utility depends on baseline health status, healthcare context, and implementation capacity rather than universal application.
Key Points
- High-dose vaccine reduces hospitalisation in older adults by modest absolute margin
- Benefits vary substantially based on individual baseline health risk profiles
- Routine preferential use across all older adults lacks evidence support
Longevity Analysis
This analysis clarifies a critical distinction in preventive medicine: demonstrating statistical efficacy does not automatically translate to clinical necessity or longevity benefit for all individuals. For older adults, the primary value lies in identifying which segments benefit most—those with compromised defense mechanisms, higher baseline disease risk, or specific comorbidities. This supports a personalized rather than categorical approach to vaccination strategy, where understanding your individual risk position and physiological capacity shapes whether enhanced protection justifies the intervention. The modest absolute benefit signals that vaccination decisions for healthy older adults should integrate additional data beyond age alone.
Original published by The Lancet Healthy Longevity, by Wenshuo Zhao, Rongna Lian, Yunli Zhao, Zhenran Li, Ming Liu, Fengwen Yang, Junhua Zhang, Jinhui Tian, Fuzhong Xue, Ya Gao.